Communiqués Cosmos Holdings Inc. OTC Markets

Actions

COSM

US2214131078

Produits pharmaceutiques

Temps Différé OTC Markets Autres places de cotation 17:14:35 05/10/2021			Varia. 5j.	Varia. 1 janv.
4,510 ^USD	-5,65%		-2,45%	-

02/07	Cosmos Health etend son programme de rachat d'actions a 3,4 millions de titres	MT
30/06	Cosmos Health Inc. (NasdaqCM:COSM) annonce un programme de rachat d'actions de 5 millions de dollars.	CI

Communiqués

06/07	Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases	GL
02/07	Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases	GL
01/07	Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace	GL
30/06	Cosmos Health Authorizes Up to $5 Million Share Repurchase Program	GL
26/06	Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units	GL
25/06	Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada	GL
24/06	Cosmos Health : C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin	PU
24/06	Cosmos Health’s C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin	GL
23/06	Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency	GL
22/06	Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit	GL
18/06	CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity	GL
17/06	Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States	GL
17/06	Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products	GL
15/06	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	GL
15/06	Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit	AQ
12/06	Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines	GL
12/06	Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit	GL
11/06	Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio	GL
11/06	Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance	GL
10/06	Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries	GL
10/06	Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway	GL
10/06	Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway	AQ
09/06	Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN	GL
08/06	Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives	GL
05/06	Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories	GL